Top 5 Peptides for Longevity – Medical Doctor’s Evidence-Based Ranking
A physician ranks five peptide categories for longevity by mechanism, evidence depth, effect size and risk, and says plainly which have human data and which do not.
Key moments
Tap a moment to play the video from there.
- 0:00Ranking criteria and scopeStillson lists his four criteria: mechanism, evidence depth, effect size and risk to benefit. He says dosing and stacks are left for future videos.
- 1:51MOTS-c as number fiveHe describes MOTS-c as a mitochondrial peptide that activates AMPK and is called exercise in a vial, and mentions SS-31 as a close sixth.
- 3:10MOTS-c lifespan and tissue dataHe covers preclinical results on aging markers, a non-significant lifespan trend of about 7%, and muscle and bone findings. He notes human data is limited to one study on an analog.
- 5:33FOXO4-DRI and senescent cellsHe explains how FOXO4-DRI is designed to release p53 so senescent cells can be cleared.
- 7:46FOXO4-DRI preclinical evidenceHe lists studies on testosterone, sperm quality, lung fibrosis and fitness in aged subjects, and notes no in vivo human data.
- 9:48Thymosin alpha 1 and immunosenescenceHe ties thymic decline to chronic inflammation and describes two mechanisms by which thymosin alpha 1 modulates immune cells.
- 12:39Thymosin alpha 1 human trialsHe cites trials in HIV, severe COVID-19 and non small cell lung cancer, and says it has been studied in over 11,000 patients.
- 16:24Who might benefit from thymosinHe suggests a CD4 to CD8 ratio under one, or a history of autoimmunity, cancer or frequent infections, as possible signals.
- 17:17Epitalon mechanismsHe covers melatonin and circadian effects, antioxidant action, DNA stability, epigenetics and telomere lengthening.
- 20:05Epitalon lifespan and cancer dataHe reports preclinical lifespan and tumor findings and a Russian epithalamin study, stressing that no epitalon human data exists.
What the video says
Quinn Stillson, who describes himself as a licensed medical doctor in longevity medicine, ranks five peptide groups for their potential to extend healthspan and lifespan. He scores each on four criteria: how strong the mechanism is, how deep the preclinical and clinical evidence is, how large the effects are, and the risk to benefit ratio. He says he will not cover dosing cycles or stacks, since several of these are not FDA approved for human use, and he frames the video as educational only.
At number five he places MOTS-c, a mitochondrial peptide he links to AMPK activation and calls an exercise mimetic. He cites preclinical work on aging markers, muscle and bone, and a late-life study where average and maximum lifespan trended about 7% higher but not significantly. He notes almost no human data and names SS-31 as a close sixth. At number four is FOXO4-DRI, a senolytic that he says frees p53 to clear senescent cells. He describes preclinical results in testosterone production, lung fibrosis and aged-animal fitness, but only one human cell study.
Thymosin alpha 1 is third. Stillson explains thymic decline and immunosenescence, then cites human trials in HIV, severe COVID-19 and cancer, and says the drug is approved in over 35 countries but not the US. He points out that none of this was done in healthy aging adults. He suggests a CD4 to CD8 ratio below one as one lab marker of when it might matter. Epitalon is second, backed by mechanisms around melatonin, antioxidant activity, DNA stability and telomeres. He reports preclinical lifespan and tumor data, including from the parent extract epithalamin, and says there is no human data on epitalon itself.
GLP-1 agonists take first place as a group. He cites meta-analyses showing a 12% lower all-cause mortality risk in people with diabetes or cardiovascular disease, larger associations in obesity from cohort studies, and a preclinical low-dose study suggesting effects beyond weight loss. He says human trials of anti-aging effects in healthy, normal-weight people are still needed.
On each compound
MOTS-c1:51
Stillson ranks MOTS-c fifth, describing it as a mitochondrial peptide that works through AMPK. He cites preclinical data on aging, muscle and bone, and says human data is very limited.
See how your DNA reads MOTS-cSS-315:00
Stillson calls SS-31 a close number six behind MOTS-c. He says it gives structural support to mitochondria and has much more human safety data.
See how your DNA reads SS-31Thymosin Alpha-19:48
Stillson ranks thymosin alpha 1 third, citing human trials in infection and cancer and approval in over 35 countries. He says direct longevity evidence in healthy adults is lacking.
See how your DNA reads Thymosin Alpha-1Epithalon17:17
Stillson ranks epitalon second on mechanism and preclinical lifespan data. He stresses that the human data he cites is for the parent extract epithalamin, not epitalon.
See how your DNA reads EpithalonSemaglutide25:31
Stillson cites a study of 17,000 patients with overweight and cardiovascular disease, where semaglutide was linked to a 20% lower risk of major cardiac events. He says only 33% of that benefit was mediated by waist circumference.
See how your DNA reads SemaglutideWhat this video doesn’t settle
- The video gives no dosing, cycle or stack guidance, and Stillson says full risk and benefit analyses are left for later videos.
- Most of the longevity evidence for MOTS-c, FOXO4-DRI and epitalon is preclinical, and Stillson says human data is absent or minimal.
- The thymosin alpha 1 immune findings come from people who were already immunocompromised, so benefit in healthy aging adults is not shown.
Questions this video answers
What are the top 5 peptides for longevity according to Quinn Stillson?
He ranks GLP-1 agonists first, epitalon second, thymosin alpha 1 third, FOXO4-DRI fourth and MOTS-c fifth. He says each earns its place for different reasons, some on mechanism and some on clinical data.
Does epitalon have human evidence for lifespan extension?
Stillson says no. The preclinical lifespan and tumor data is on epitalon or the parent extract epithalamin, and the one human study he mentions used epithalamin. He says safety and efficacy cannot be assumed for epitalon.
What does Stillson say about thymosin alpha 1 and aging?
He says it has been studied in over 11,000 patients and may counter immunosenescence, but the trials he cites were in people with HIV, severe COVID-19 or cancer. He says direct evidence in healthy aging adults is missing.
Why does Stillson rank GLP-1 agonists first for longevity?
He cites meta-analyses showing a 12% lower all-cause mortality risk and cohort data in obesity, plus mechanisms such as lower inflammation and neuroprotection. He says a preclinical low-dose study hints at benefit without weight loss.
Video by Quinn Stillson MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
